The price of many existing drugs, both brand and generic, can increase substantially over time, and questions are frequently raised regarding whether these price increases are justified. State policymakers have been particularly active in seeking measures to address this issue. In 2019, we launched a new line of ICER reports, named Unsupported Price Increase (UPI) reports, […]
This California Unsupported Price Increase final report is based on drugs identified through SB-17, the California drug price transparency law. ICER found that increases in spending for many drugs under the SB-17 law may be primarily due to increased volume rather than increases in net price. Final Documents ICER’s Chief Medical Officer David Rind, MD […]
The price of many existing drugs, both brand and generic, can increase substantially over time, and questions are frequently raised regarding whether these price increases are justified. State policymakers have been particularly active in seeking measures to address this issue. For example, both California and Vermont now have laws tracking substantial drug price increases, requiring drug manufacturers […]
ICER evaluated selected high-impact drugs with substantial price increases. ICER reviewed changes in the evidence base for each of these drugs and assess whether or not new clinical data exists that could suggest that the drugs could be significantly more beneficial for patients than what was previously understood. ICER published the final draft of its […]
On January 12, 2021, ICER published our latest report on Unsupported Price Increases (UPI) of prescription drugs in the United States. Among the top drugs with price increases in 2019 that had substantial effects on US spending, ICER determined that seven of 10 lacked adequate new evidence to demonstrate a substantial clinical benefit that was not […]
Recent Comments